Additive manufacturing MicroFactory for amorphous solid dispersion formulations

Elke Prasad; John Robertson; Gavin Halbert

Additive manufacturing MicroFactory for amorphous solid dispersion formulations

Elke Prasad, John Robertson, Gavin Halbert

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Poster

3 Downloads (Pure)

Abstract

This study utilised the HUB Additive-Manufacturing-MicroFactory as an enabler for the streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® and Plasdone S-630 Ultra as a superior polymers to form stable ASD formulation with Ritonavir.

The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® and Plasdone S-630 Ultra were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

Original language	English
Publication status	Published - 16 Sept 2024
Event	CMAC Showcase 2024 - TIC, Glasgow, United Kingdom Duration: 16 Sept 2024 → 16 Sept 2024

Conference

Conference	CMAC Showcase 2024
Country/Territory	United Kingdom
City	Glasgow
Period	16/09/24 → 16/09/24

Keywords

additive manufacturing (AM)
amorphous solid dispersion (ASD)
MicroFactory

Access to Document

Prasad-etal-ElPr_Showcase2024_Additive_manufacturing_MicroFactory_for_amorphous_solid_dispersion_formulationsFinal published version, 1.53 MBLicence: CC BY-NC 4.0

1 Poster
1 Article

An Additive Manufacturing MicroFactory: overcoming brittle material failure and improving product performance through tablet microstructure control for an immediate release dose form
Prasad, E., Robertson, J. & Halbert, G. W., 11 Sept 2024, In: Polymers. 16, 18, 23 p., 2566.
Research output: Contribution to journal › Article › peer-review

Open Access
File
15 Downloads (Pure)
3D printing MicroFactory for amorphous solid dispersion formulations
Prasad, E., Hueckman, J., Bordos, E., Robertson, J. & Halbert, G. W., 14 Jul 2024. 1 p.
Research output: Contribution to conference › Poster

Open Access
File

Cite this

@conference{da63b2b8fde441f68fa4909ee362755d,

title = "Additive manufacturing MicroFactory for amorphous solid dispersion formulations",

abstract = "This study utilised the HUB Additive-Manufacturing-MicroFactory as an enabler for the streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus{\textregistered} (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus{\textregistered} and Plasdone S-630 Ultra as a superior polymers to form stable ASD formulation with Ritonavir.The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus{\textregistered} and Plasdone S-630 Ultra were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).",

keywords = "additive manufacturing (AM), amorphous solid dispersion (ASD), MicroFactory",

author = "Elke Prasad and John Robertson and Gavin Halbert",

year = "2024",

month = sep,

day = "16",

language = "English",

note = "CMAC Showcase 2024 ; Conference date: 16-09-2024 Through 16-09-2024",

}

TY - CONF

T1 - Additive manufacturing MicroFactory for amorphous solid dispersion formulations

AU - Prasad, Elke

AU - Robertson, John

AU - Halbert, Gavin

PY - 2024/9/16

Y1 - 2024/9/16

N2 - This study utilised the HUB Additive-Manufacturing-MicroFactory as an enabler for the streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® and Plasdone S-630 Ultra as a superior polymers to form stable ASD formulation with Ritonavir.The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® and Plasdone S-630 Ultra were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

AB - This study utilised the HUB Additive-Manufacturing-MicroFactory as an enabler for the streamlined manufacture of Amorphous Solid Dispersion (ASD) formulation of the model compound Ritonavir with an immediate release polymer Soluplus® (BASF). The Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP) research program identified Soluplus® and Plasdone S-630 Ultra as a superior polymers to form stable ASD formulation with Ritonavir.The drug release from 3D printed (3DP) Ritonavir ASD formulations with Soluplus® and Plasdone S-630 Ultra were compared to a commercial product (Norvir, 100mg, Abbvie Ltd).

KW - additive manufacturing (AM)

KW - amorphous solid dispersion (ASD)

KW - MicroFactory

M3 - Poster

T2 - CMAC Showcase 2024

Y2 - 16 September 2024 through 16 September 2024

ER -

Additive manufacturing MicroFactory for amorphous solid dispersion formulations

Abstract

Conference

Keywords

Access to Document

Fingerprint

Research output

An Additive Manufacturing MicroFactory: overcoming brittle material failure and improving product performance through tablet microstructure control for an immediate release dose form

3D printing MicroFactory for amorphous solid dispersion formulations

Cite this